Literature DB >> 25502874

Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study.

Renato Valenti1, Rossella Marcucci, Davide Capodanno, Giuseppe De Luca, Angela Migliorini, Anna Maria Gori, Guido Parodi, Betti Giusti, Nazario Carrabba, Rita Paniccia, Giulia Cantini, Marco Marrani, Gian Franco Gensini, Rosanna Abbate, David Antoniucci.   

Abstract

The aim of this study was the identification of the optimal cutoff value of high residual platelet reactivity (HRPR) assessed by light transmission aggregometry (LTA) in the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) patient cohort to discriminate patients with and without major adverse cardiac events (MACE) and cardiac death at 2 years. The RECLOSE 2-ACS study included 1,789 patients with ACS who underwent LTA after clopidogrel loading. A post hoc cutoff value for HRPR was defined with the ROC curve and the Youden index and compared with the protocol-defined cutoff of 70 %. By ROC analysis, 63 % resulted the optimal cutoff value to predict both MACE and cardiac death at 2 years follow-up. A significant sensitivity improvement for the ROC-based cutoff value was noted (p < 0.001), at the price of lower specificity and predictive accuracy. The latter were 81 % for MACE and 85 % for cardiac death with the 70 % cutoff, while the respective figures were 73 and 75 % with the 63 % cutoff. The areas under the curve were virtually identical with the 70 and 63 % cutoffs both for MACE (0.71) and cardiac death (0.79). A residual platelet reactivity cutoff of 70 % by LTA, compared to the ROC-based cutoff of 63 %, allows for the identification of a subset of patients at very high risk of adverse ischemic events, making LTA-ADP test more acceptable in clinical practice for the identification of subjects at risk than other platelet function assays with broader definitions of HRPR.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25502874     DOI: 10.1007/s11239-014-1159-1

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  21 in total

1.  High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.

Authors:  Guido Parodi; Rossella Marcucci; Renato Valenti; Anna Maria Gori; Angela Migliorini; Betti Giusti; Piergiovanni Buonamici; Gian Franco Gensini; Rosanna Abbate; David Antoniucci
Journal:  JAMA       Date:  2011-09-21       Impact factor: 56.272

2.  Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation.

Authors:  Paul Barragan; Jean-Louis Bouvier; Pierre-Olivier Roquebert; Gilles Macaluso; Philippe Commeau; Bertrand Comet; Antoine Lafont; Laurence Camoin; Ulrich Walter; Martin Eigenthaler
Journal:  Catheter Cardiovasc Interv       Date:  2003-07       Impact factor: 2.692

3.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

4.  Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.

Authors:  Paul A Gurbel; Kevin P Bliden; Kirk Guyer; Peter W Cho; Kazi A Zaman; Rolf P Kreutz; Ashwani K Bassi; Udaya S Tantry
Journal:  J Am Coll Cardiol       Date:  2005-10-21       Impact factor: 24.094

5.  Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.

Authors:  Udaya S Tantry; Laurent Bonello; Daniel Aradi; Matthew J Price; Young-Hoon Jeong; Dominick J Angiolillo; Gregg W Stone; Nick Curzen; Tobias Geisler; Jurrien Ten Berg; Ajay Kirtane; Jolanta Siller-Matula; Elisabeth Mahla; Richard C Becker; Deepak L Bhatt; Ron Waksman; Sunil V Rao; Dimitrios Alexopoulos; Rossella Marcucci; Jean-Luc Reny; Dietmar Trenk; Dirk Sibbing; Paul A Gurbel
Journal:  J Am Coll Cardiol       Date:  2013-09-27       Impact factor: 24.094

Review 6.  Platelet function monitoring in patients with coronary artery disease.

Authors:  Paul A Gurbel; Richard C Becker; Kenneth G Mann; Steven R Steinhubl; Alan D Michelson
Journal:  J Am Coll Cardiol       Date:  2007-10-23       Impact factor: 24.094

7.  Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events.

Authors:  L Bonello; F Paganelli; M Arpin-Bornet; P Auquier; J Sampol; F Dignat-George; P Barragan; L Camoin-Jau
Journal:  J Thromb Haemost       Date:  2007-05-07       Impact factor: 5.824

8.  Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.

Authors:  Shlomi Matetzky; Boris Shenkman; Victor Guetta; Michael Shechter; Roy Beinart; Roy Bienart; Ilan Goldenberg; Ilya Novikov; Hanna Pres; Naphtali Savion; David Varon; Hanoch Hod
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690

9.  High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.

Authors:  Angela Migliorini; Renato Valenti; Rossella Marcucci; Guido Parodi; Gabriele Giuliani; Piergiovanni Buonamici; Giampaolo Cerisano; Nazario Carrabba; Gian Franco Gensini; Rosanna Abbate; David Antoniucci
Journal:  Circulation       Date:  2009-11-16       Impact factor: 29.690

10.  Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.

Authors:  Thomas Cuisset; Corinne Frere; Jacques Quilici; Bénédicte Gaborit; Christel Castelli; Raphael Poyet; Laurent Bali; Pierre-Emmanuel Morange; Marie-Christine Alessi; Jean-Louis Bonnet
Journal:  Am J Cardiol       Date:  2009-10-15       Impact factor: 2.778

View more
  11 in total

1.  High residual platelet reactivity (HRPR) for adenosine diphosphate (ADP) stimuli is a determinant factor for long-term outcomes in acute ischemic stroke with anti-platelet agents: The meaning of HRPR after ADP might be more prominent in large atherosclerotic infarction than other subtypes of AIS.

Authors:  Jae-Kwan Cha; Hyun-Seok Park; Hyun-Wook Nah; Dae-Hyun Kim; Myong-Jin Kang; Jae-Hyung Choi; Jae-Taeck Huh; Hyun-Kyung Suh
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

2.  Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease.

Authors:  Michele Massimo Gulizia; Furio Colivicchi; Maurizio Giuseppe Abrignani; Marco Ambrosetti; Nadia Aspromonte; Gabriella Barile; Roberto Caporale; Giancarlo Casolo; Emilia Chiuini; Andrea Di Lenarda; Pompilio Faggiano; Domenico Gabrielli; Giovanna Geraci; Alessio Gaetano La Manna; Aldo Pietro Maggioni; Alfredo Marchese; Ferdinando Maria Massari; Gian Francesco Mureddu; Giuseppe Musumeci; Federico Nardi; Antonio Vittorio Panno; Roberto Franco Enrico Pedretti; Massimo Piredda; Enrico Pusineri; Carmine Riccio; Roberta Rossini; Fortunato Scotto di Uccio; Stefano Urbinati; Ferdinando Varbella; Giovanni Battista Zito; Leonardo De Luca
Journal:  Eur Heart J Suppl       Date:  2018-05-31       Impact factor: 1.803

3.  Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy.

Authors:  Patricia P Wadowski; Beate Eichelberger; Christoph W Kopp; Joseph Pultar; Daniela Seidinger; Renate Koppensteiner; Irene M Lang; Simon Panzer; Thomas Gremmel
Journal:  J Cardiovasc Transl Res       Date:  2017-04-19       Impact factor: 4.132

4.  Genomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of Clopidogrel.

Authors:  W-P Zhong; H Wu; J-Y Chen; X-X Li; H-M Lin; B Zhang; Z-W Zhang; D-L Ma; S Sun; H-P Li; L-P Mai; G-D He; X-P Wang; H-P Lei; H-K Zhou; L Tang; S-W Liu; S-L Zhong
Journal:  Clin Pharmacol Ther       Date:  2017-02-09       Impact factor: 6.875

5.  Platelet Activation and Clopidogrel Effects on ADP-Induced Platelet Activation in Cats with or without the A31P Mutation in MYBPC3.

Authors:  R H L Li; J A Stern; V Ho; F Tablin; S P Harris
Journal:  J Vet Intern Med       Date:  2016-09-12       Impact factor: 3.333

6.  Clinical outcomes in patients treated for coronary in-stent restenosis with drug-eluting balloons: Impact of high platelet reactivity.

Authors:  Adrienn Tornyos; Dániel Aradi; Iván G Horváth; Attila Kónyi; Balázs Magyari; Tünde Pintér; András Vorobcsuk; Dániel Tornyos; András Komócsi
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

7.  Impact of Obstructive Sleep Apnea on Platelet Function Profiles in Patients With Acute Coronary Syndrome Taking Dual Antiplatelet Therapy.

Authors:  Wei Gong; Xiao Wang; Jingyao Fan; Shaoping Nie; Yongxiang Wei
Journal:  J Am Heart Assoc       Date:  2018-08-07       Impact factor: 5.501

8.  Clinical Implications of "Tailored" Antiplatelet Therapy in Patients With Chronic Total Occlusion.

Authors:  Maria Grazia De Gregorio; Rossella Marcucci; Angela Migliorini; Anna Maria Gori; Betti Giusti; Ruben Vergara; Rita Paniccia; Nazario Carrabba; Niccolò Marchionni; Renato Valenti
Journal:  J Am Heart Assoc       Date:  2020-02-11       Impact factor: 5.501

9.  Clopidogrel versus ticagrelor in the treatment of Chinese patients undergoing percutaneous coronary intervention: effects on platelet function assessed by platelet function tests and mean platelet volume.

Authors:  Yang Zhang; Rui Peng; Xiaojuan Li; Gaowa Cheng; Ximing Wang; Jinxing Yu; Muxing Hua; Xi Chen; Zhou Zhou
Journal:  Thromb J       Date:  2021-12-07

10.  Comparison of Light Transmission Aggregometry With Impedance Aggregometry in Patients on Potent P2Y12 Inhibitors.

Authors:  Patricia P Wadowski; Joseph Pultar; Constantin Weikert; Beate Eichelberger; Irene M Lang; Renate Koppensteiner; Simon Panzer; Thomas Gremmel
Journal:  J Cardiovasc Pharmacol Ther       Date:  2020-10-27       Impact factor: 2.457

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.